Potential conflict of interest: Dr. Balagopal advises Merck. Dr. Sulkowski advises and received grants from Gilead and Merck. Dr. Ray consults for Boehringer Ingelheim.
Antiretroviral therapy, interferon sensitivity, and virologic setpoint in human immunodeficiency virus/hepatitis C virus coinfected patients
Article first published online: 14 MAY 2014
© 2014 by the American Association for the Study of Liver Diseases
Volume 60, Issue 2, pages 477–486, August 2014
How to Cite
Balagopal, A., Kandathil, A. J., Higgins, Y. H., Wood, J., Richer, J., Quinn, J., Eldred, L., Li, Z., Ray, S. C., Sulkowski, M. S. and Thomas, D. L. (2014), Antiretroviral therapy, interferon sensitivity, and virologic setpoint in human immunodeficiency virus/hepatitis C virus coinfected patients. Hepatology, 60: 477–486. doi: 10.1002/hep.27158
Supported by R37 DA 013806, R01 DA 016078 and 1P30AI094189. This publication was made possible by the Johns Hopkins Institute for Clinical and Translational Research (ICTR) which is funded in part by Grant Number UL1 TR 000424-06 through a Clinical and Translational Science Award (CTSA) from the National Center for Advancing Translational Sciences (NCATS) a component of the National Institutes of Health (NIH), and NIH Roadmap for Medical Research. Its contents are solely the responsibility of the authors and do not necessarily represent the official view of the Johns Hopkins ICTR, NCATS, or NIH. Tenofovir DF and emtricitabine were donated by Gilead. Peginterferon alfa 2b and raltegravir were donated by Merck.
- Issue published online: 22 JUL 2014
- Article first published online: 14 MAY 2014
- Accepted manuscript online: 5 APR 2014 03:58AM EST
- Manuscript Accepted: 2 APR 2014
- Manuscript Revised: 14 MAR 2014
- Manuscript Received: 11 NOV 2013